ChiRhoClin has relaunched an orphan drug product,ChiRhoStim(Human Secretin for Injection)used to diagnose pancreatic cancer and pancreatic exocrine dysfunction.
The company has received permission to market the current batch of ChiRhoStim till its new manufacturing site becomes operational by the beginning of 2013.
ChiRhoStim facilitates cannulation during ERCP,Gastrinoma testing and also allows the use of the pancreatic fluid secretions in situ for imaging modalities such as MRCP,CT,EUS after secretin stimulation.
ChiRhoClin marketing and operations VP Skip Purich said ChiRhoClin aims to generate grants to help fund pancreatic research for the medical community.
''With the release of ChiRhoStim®,researchers studying the pancreas now have a tool that can facilitate their research,"Purich added.
The company could relaunch the product with the cooperation of FDA CDER Drug Shortage Team,pancreatic community,pharmacists,doctors,nurses and especially the patients.
